Press Room

2022 CPhI North America

Start
Tuesday, May 17, 2022 - 08:00
End
Thursday, May 19, 2022 - 17:00
Location: Philadelphia, USA
Booth Number: 723
Hovione present at the CPhI NA 2022 in Philadelphia

 

 

We are ready to safely return to CPhI North America in Philadelphia and we look forward to seeing you.



If you would like to connect face-to-face with Hovione’s team at our booth (#723) or if you still prefer to meet us online, always count on our expert’s support. Schedule a meeting with us, our colleagues will be pleased to meet you, both in-person or online.

 

Schedule a meeting button | Hovione
 



































 

Hovione offers the best chemistry, particle engineering and drug product capabilities all at the same location. With over 60 years’ experience in process development and manufacturing, we combine our innovative science, the most up-to-date technologies, and multidisciplinary teams to deliver the most impeccable end-to-end solutions, enabling your projects to go to market faster.

 

Find more about CPhI North America











 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026